Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Media

Monday’s most followed in U.S. including Intel, Altera, Microsoft, Rosetta Stone, Bristol-Myers, Celladon, CTi BioPharma, Molycorp, OM Group, Dollar Tree, Citigroup

U.S. shares fluctuated today as investors assessed a mixed bag of economic reports including consumer spending, construction and manufacturing. The S&P 500 (INDEXSP:.INX) was little changed at 2,108 at 11:39 a.m. in New York. The 30-company Dow Jones Industrial Average (INDEXDJX:.DJI) added less than 0.1 percent at 18,022, and the tech-heavy Nasdaq Composite (INDEXNASDAQ:.IXIC) was up less than 0.1 percent at 5,071. Most followed shares included Intel, Altera, Microsoft, Rosetta Stone, Bristol-Myers Squibb, Celladon, CTi BioPharma, Moycorp, OM Group, Dollar Tree, and Citigroup.

In technology shares, Intel (NASDAQ:INTC) surrendered 1.5 percent to $33.93 as the world’s largest chipmaker said it agreed to buy Altera (NASDAQ:ALTR) for $16.7 billion in a deal that will take out yet another chipmaker and add to a record year for industry consolidation. Intel will pay $54 a share in cash for the maker of programmable logic semiconductors, the companies said in a statement today. That’s a premium of 11 percent over Altera’s closing share price on Friday. Shares of Altera gained 6.2 percent to $51.86.

Microsoft (NASDAQ:MSFT) added 0.5 percent to $47.11 as the world's largest software company said today that its new Windows 10 operating system will be available worldwide on July 29, as a free upgrade for users of the most recent versions of Windows.

Rosetta Stone (NYSE:RST) slipped 0.5 percent to $7.58 after saying it is evaluating an “expression of interest” it received from New York investment firm RDG Capital Fund Management.

In health-care shares, Bristol-Myers Squibb (NYSE:BMY) added 3.8 percent to $67.04 as a cancer drug that works by unleashing the body’s immune system extended survival rates for lung-cancer patients compared with chemotherapy in a clinical trial. But the results fell short of Wall Street expectations.

Celladon (NASDAQ:CLDN) climbed 4.3 percent to $2.41 after the clinical-stage biotechnology company said it will seek an acquisition or partnership and named Paul Cleveland chief executive.

CTi BioPharma (NASDAQ:CTIC) jumped 16 percent to $2.24 in heavy trading after the drug developer presented positive data on its blood cancer drug.

In materials, Molycorp (NYSE:MCP) fell 12.1 percent to $0.466 after the Wall Street Journal reported the rare earth miner is expected to skip a loan payment, which might lead to a bankruptcy filing.

OM Group (NYSE:OMG) jumped 28 percent to $33.90 after the technology-driven industrial company agreed to be taken private by Apollo Global Management (NYSE:APO) for $34 a share, or a total of about $1 billion.

In other stocks, Dollar Tree (NASDAQ:DLTR) plans to sell 330 stores to private-equity firm Sycamore Partners, addressing regulatory concerns related to its planned merger with Family Dollar Stores (NYSE:FDO).

In financial stocks, Citigroup (NYSE:C) gained 1.1 percent to $54.68 on a Wall Street Journal report that the bank is expected to close its troubled Banamex USA unit. Goldman Sachs boosted the stock to "buy" from "neutral".

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK